TAMOXIFEN CITRATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tamoxifen Citrate, and when can generic versions of Tamoxifen Citrate launch?
Tamoxifen Citrate is a drug marketed by Actavis Labs Fl Inc, Aegis Pharms, Apotex, Dr Reddys Labs Sa, Eugia Pharma, Ivax Sub Teva Pharms, Mylan, Pharmachemie, Roxane, Teva, and Zydus Pharms. and is included in twelve NDAs.
The generic ingredient in TAMOXIFEN CITRATE is tamoxifen citrate. There are sixteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the tamoxifen citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tamoxifen Citrate
A generic version of TAMOXIFEN CITRATE was approved as tamoxifen citrate by ACTAVIS LABS FL INC on February 20th, 2003.
Summary for TAMOXIFEN CITRATE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 12 |
Finished Product Suppliers / Packagers: | 12 |
Raw Ingredient (Bulk) Api Vendors: | 93 |
Clinical Trials: | 125 |
Patent Applications: | 4,521 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TAMOXIFEN CITRATE |
DailyMed Link: | TAMOXIFEN CITRATE at DailyMed |
Recent Clinical Trials for TAMOXIFEN CITRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sharif Medical Research Center | Phase 2 |
Baylor College of Medicine | Early Phase 1 |
James Dowling | Phase 1/Phase 2 |
Pharmacology for TAMOXIFEN CITRATE
Drug Class | Estrogen Agonist/Antagonist |
Mechanism of Action | Selective Estrogen Receptor Modulators |